These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37116624)

  • 1. Effects of Plant-Based Protein Consumption on Kidney Function and Mineral Bone Disorder Outcomes in Adults With Stage 3-5 Chronic Kidney Disease: A Systematic Review.
    Burstad KM; Cladis DP; Wiese GN; Butler M; Hill Gallant KM
    J Ren Nutr; 2023 Nov; 33(6):717-730. PubMed ID: 37116624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary interventions for mineral and bone disorder in people with chronic kidney disease.
    Liu Z; Su G; Guo X; Wu Y; Liu X; Zou C; Zhang L; Yang Q; Xu Y; Ma W
    Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD010350. PubMed ID: 26376110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary Protein Intake and Bone Across Stages of Chronic Kidney Disease.
    Stremke ER; Biruete A; Hill Gallant KM
    Curr Osteoporos Rep; 2020 Jun; 18(3):247-253. PubMed ID: 32240477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A meta-analysis of randomized controlled trials of tonifying kidney and strengthen bone therapy on nondialysis patients with chronic kidney disease-mineral and bone disorder.
    Wu G; Li L; Wu Z
    Medicine (Baltimore); 2023 Jun; 102(25):e34044. PubMed ID: 37352066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha is associated with mineral bone disorder and growth impairment in children with chronic kidney disease.
    Meza K; Biswas S; Zhu YS; Gajjar A; Perelstein E; Kumar J; Akchurin O
    Pediatr Nephrol; 2021 Jun; 36(6):1579-1587. PubMed ID: 33387018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
    Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
    Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe].
    Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D
    Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C; Cheng C; Wang J; Zhang L; Purrunsing Y; Yang G; Zeng M; Huang H; Ren W; Ye Y; Ma H; Xing C; Wang N
    Clin Nephrol; 2020 Feb; 93(2):65-76. PubMed ID: 31793871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.
    Chuang SH; Wong HC; Vathsala A; Lee E; How PP
    Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitamin D Therapy in Adults With CKD: A Systematic Review and Meta-analysis.
    Yeung WG; Palmer SC; Strippoli GFM; Talbot B; Shah N; Hawley CM; Toussaint ND; Badve SV
    Am J Kidney Dis; 2023 Nov; 82(5):543-558. PubMed ID: 37356648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
    Meng Y; Zhang H; Li Y; Li Q; Zuo L
    Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients.
    Karaboyas A; Muenz D; Fuller DS; Desai P; Lin TC; Robinson BM; Rossetti S; Pisoni RL
    Am J Kidney Dis; 2022 Mar; 79(3):362-373. PubMed ID: 34273436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA.
    Sekercioglu N; Angeliki Veroniki A; Thabane L; Busse JW; Akhtar-Danesh N; Iorio A; Cruz Lopes L; Guyatt GH
    PLoS One; 2017; 12(3):e0171028. PubMed ID: 28248961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
    Yamada S; Nakano T
    J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated network pharmacology, transcriptomics, and metabolomics analysis to reveal the mechanism of salt Eucommiae cortex in the treatment of chronic kidney disease mineral bone disorders via the PPARG/AMPK signaling pathway.
    Shen J; Liu Y; Wang Q; Chen H; Hu Y; Guo X; Liu X; Li Y
    J Ethnopharmacol; 2023 Oct; 314():116590. PubMed ID: 37207881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CKD-MBD Syndrome: Hysteresis in PTH Involvement and PTH Administration for Its Management.
    Pazianas M; Miller PD
    J Bone Miner Res; 2020 Dec; 35(12):2313-2317. PubMed ID: 32780482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.